154 related articles for article (PubMed ID: 33049542)
1. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
2. Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.
Comito F; Leslie I; Boos L; Furness A; Pickering L; Turajlic S; Larkin J
J Immunother; 2020 Oct; 43(8):250-255. PubMed ID: 32796274
[TBL] [Abstract][Full Text] [Related]
3. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
5. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
Ozluk AA; Karateke M; Sanli UA; Karaca B
Melanoma Res; 2023 Oct; 33(5):417-421. PubMed ID: 37276020
[TBL] [Abstract][Full Text] [Related]
7. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
8. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
Maslov DV; Tawagi K; Kc M; Simenson V; Yuan H; Parent C; Bamnolker A; Goel R; Blake Z; Matrana MR; Johnson DH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226279
[TBL] [Abstract][Full Text] [Related]
9. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.
Sia TY; Wan V; Finlan M; Zhou QC; Iasonos A; Zivanovic O; Sonoda Y; Chi DS; Long Roche K; Jewell E; Tew WP; O'Cearbhaill RE; Cohen S; Makker V; Liu YL; Friedman CF; Kyi C; Zamarin D; Gardner G
Int J Gynecol Cancer; 2024 Apr; 34(4):594-601. PubMed ID: 38296517
[TBL] [Abstract][Full Text] [Related]
10. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Mahmood U; Huynh MA; Killoran JH; Qian JM; Bent EH; Aizer AA; Mak RH; Mamon HJ; Balboni TA; Gunasti L; Ott PA; Awad MM; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):666-675. PubMed ID: 35643252
[TBL] [Abstract][Full Text] [Related]
12. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
13. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Matsumoto H; Hirano K; Kominami R; Tomii K; Suzuki H; Hirashima T; Tanaka S; Uchida J; Morita M; Kanazu M; Mori M; Nagata K; Fukuda I; Tamiya M
BMC Cancer; 2021 Apr; 21(1):346. PubMed ID: 33794809
[TBL] [Abstract][Full Text] [Related]
15. Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade.
Klemen ND; Court CM; Fernandes MC; Walch HS; Chatila WK; Saadat LV; Maron S; Crane C; Shia J; Cercek A; Gönen M; Schultz ND; Garcia Aguilar J; Jarnagin WR; D'Angelica MI
Ann Surg Oncol; 2022 Dec; 29(13):8373-8382. PubMed ID: 35930112
[TBL] [Abstract][Full Text] [Related]
16. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
[TBL] [Abstract][Full Text] [Related]
17. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
18. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.
Zhuo N; Liu C; Zhang Q; Li J; Zhang X; Gong J; Lu M; Peng Z; Zhou J; Wang X; Jiao X; Wang Y; Wang Y; Gao M; Shen L; Lu Z
JAMA Netw Open; 2022 Mar; 5(3):e224637. PubMed ID: 35348710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
